ImmunityBio will manufacture the vaccine once human trials are successfully completed in South Africa. Amyris will contribute its RNA technology licensed from the Infectious Disease Research Institute, as well as provide sustainable squalene, an organic compound used to produce the vaccine.

Once human trials are completed successfully, Amyris and ImmunityBio hope to deliver 1 billion doses of the new vaccine in 2022 to address vaccine access in developing countries and other regions of the world.

A definitive agreement is in process and is expected to be executed within the next month pending standard closing conditions.

ImmunityBio, NantOmics identify personalized immunotherapy targets
ImmunityBio and NantOmics are sharing a new approach they have developed for identifying and validating neoepitope and neoepitope-reactive T cells for...

Early data suggest ImmunityBio's COVID-19 vaccine is effective
ImmunityBio has reported initial data from a phase I trial suggesting its COVID-19 vaccine candidate stimulates the generation of T cells reactive to...

Amyris, IDRI post positive preclinical results for COVID-19 vaccine
Amyris, in partnership with the Infectious Disease Research Institute (IDRI), has released preliminary data from a preclinical study of its RNA COVID-19...

Amyris, IDRI to partner on RNA vaccines
Amyris and the Infectious Disease Research Institute (IDRI) have announced that they will collaborate on the development of a new RNA vaccine platform,...

Amyris partners with IDRI on scalable vaccine platform
Amyris and the Infectious Disease Research Institute (IDRI) have inked a binding term sheet for the development of a planned COVID-19 RNA vaccine technology...